Related Experiment Video
Updated: Jun 18, 2026

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
Published on: May 28, 2019
Tenecteplase for ST-elevation myocardial infarction in a patient treated with drotrecogin alfa (activated) for severe
Lillian Barra1, Jeffrey Shum, J Geoffrey Pickering
1Division of Critical Care, Department of Medicine, University of Western Ontario, Commissioner's Rd, London, Ontario, Canada.
Introduction:
Drotrecogin alfa (activated) (DrotAA), an activated protein C, promotes fibrinolysis in patients with severe sepsis. There are no reported cases or studies that address the diagnosis and treatment of myocardial infarction in septic patients treated with DrotAA.
Case Presentation:
A 59-year-old Caucasian man with septic shock secondary to community-acquired pneumonia treated with DrotAA, subsequently developed an ST-elevation myocardial infarction 12 hours after starting DrotAA. DrotAA was stopped and the patient was given tenecteplase thrombolysis resulting in complete resolution of ST-elevation and no adverse bleeding events. DrotAA was restarted to complete the 96-hour course. The sepsis resolved and the patient was discharged from hospital.
Conclusion:
In patients with severe sepsis or septic shock complicated by myocardial infarction, it is difficult to determine if the myocardial infarction is an isolated event or caused by the sepsis process. The efficacy and safety of tenecteplase thrombolysis in septic patients treated with DrotAA need further study.
Related Concept Videos
Acute Coronary Syndrome I: Introduction
Acute Coronary Syndrome IV: Interprofessional Care
Cardiopulmonary Resuscitation IV: Pharmacological Management
Diphtheria
